Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

Spruce Biosciences, the US-based endocrine disorder drug developer backed by pharmaceutical firm Novo, closed its initial public offering at approximately $104m yesterday. The company raised an initial $90m when it floated on Friday last week having priced 6 million shares at $15.00 each. Its share price closed at $17.85 yesterday and the IPO’s underwriters have…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.